Wednesday, July 8, 2026

Patent intelligence · US

US 12350242

Binge behavior regulators

granted A61KA61K31/135A61K31/255A61K31/357
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 5
Related coverage 1
Patent details — US 12350242

Quick answer

US 12350242 (Binge behavior regulators) is held by CLEARMIND MEDICINE INC.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/135, A61K31/255, A61K31/357, A61K31/36, A61K31/40

More from CLEARMIND MEDICINE INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12357590

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Expires Jul 10, 2045

    granted
  2. US 12064402

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Expires Aug 15, 2044

    granted
  3. US 11528924

    Alcoholic beverage substitutes

    CLEARMIND MEDICINE INC. · Expires Dec 15, 2042

    granted
  4. US 11077072

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Expires Jul 29, 2041

    granted

Related coverage

Frequently asked questions

What is US patent 12350242?

US 12350242 (Binge behavior regulators) is held by CLEARMIND MEDICINE INC.. Status: granted. Granted Jul 8, 2025. Expires Jul 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12350242?

CLEARMIND MEDICINE INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.

When does US 12350242 expire?

Our index shows an expiration date of Jul 3, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.